Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Change in Account Payables: 2009-2025

Historic Change in Account Payables for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to -$1.7 million.

  • Lifecore Biomedical's Change in Account Payables rose 150.70% to $1.0 million in Q2 2025 from the same period last year, while for May 2025 it was -$1.7 million, marking a year-over-year increase of 74.99%. This contributed to the annual value of -$1.7 million for FY2025, which is 74.99% up from last year.
  • According to the latest figures from FY2025, Lifecore Biomedical's Change in Account Payables is -$1.7 million, which was up 74.99% from -$6.7 million recorded in FY2024.
  • Lifecore Biomedical's Change in Account Payables' 5-year high stood at $16.0 million during FY2023, with a 5-year trough of -$6.7 million in FY2024.
  • Moreover, its 3-year median value for Change in Account Payables was -$1.7 million (2025), whereas its average is $2.6 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Change in Account Payables slumped by 378.94% in 2021, and later skyrocketed by 256.19% in 2022.
  • Yearly analysis of 5 years shows Lifecore Biomedical's Change in Account Payables stood at -$6.0 million in 2021, then surged by 256.19% to $9.3 million in 2022, then soared by 71.66% to $16.0 million in 2023, then crashed by 141.63% to -$6.7 million in 2024, then soared by 74.99% to -$1.7 million in 2025.